AbbVie will present positive data from a Phase 3 study evaluating Humira (adalimumab) in patients with moderate to severe fingernail psoriasis at the Psoriasis 2016 – 5th Congress of the Psoriasis International Network on July 7-9 in Paris, France.
The Phase 3 study is a multicenter, double-blind, randomized, parallel-arm, placebo-controlled trial evaluating the safety and efficacy of Humira vs. placebo in patients with moderate to severe fingernail psoriasis and moderate to severe chronic plaque psoriasis. The co-primary endpoints were at least a 75% improvement in the modified Nail Psoriasis Severity Index (mNAPSI) and achievement of Physician’s Global Assessment-fingernail-psoriasis of 0 (clear) or 1 (minimal) with at least a 2-point improvement from baseline.
Findings from the study showed that patients treated with Humira met both primary endpoints at Week 26, with 46.6% of patients achieving at least 75% improvement in mNAPSI vs. 3.4% for placebo (P<0.001) and 48.9% achieving Physician’s Global Assessment-fingernail-psoriasis of 0 or 1 vs. 6.9% in the placebo group (P<0.001). The study also found a tolerable safety profile for Humira through 26 weeks, with comparable adverse event rates to placebo.
Humira is a tumor necrosis factor (TNF) blocker currently approved for the treatment of chronic plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease,ulcerative colitis, hidradenitis suppurativa, and most recently, for non-infectious panuveitis.
For more information call (800) 633-9110 or visit Abbvie.com.